Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis
2024/06/21 by Lauren Pischel, Brett A. Martini, Natalle Yu +10 · 31 citations
Immunology and Microbiology · Medicine · #Poxvirus research and outbreaks #Immune responses and vaccinations #SARS-CoV-2 and COVID-19 Research
paper · doi:10.1016/j.vaccine.2024.06.021
Abstract
INTRODUCTION: Before the global mpox outbreak which began in 2022, the real-world vaccine effectiveness (VE) of mpox vaccines was unknown. We quantified the VE in the global population of 3rd generation or later mpox vaccines (MVA-BN, LC16m8, OrthopoxVac) compared with unvaccinated or other vaccinated states for infection, hospitalization and death. VE was stratified by 1-dose and 2-doses and post-exposure prophylaxis (PEP). METHODS: Studies were included if they measured vaccine efficacy or effectiveness in humans. Animal studies and immunogenicity studies were excluded. MEDLINE, Web of Science, Google Scholar, Embase, MedRxiv and grey literature were searched from January 1st, 1970, with the last search run on November 3, 2023 (Prospero, CRD42022345240). Risk of publication bias was assessed via funnel plots and Egger's test, and study quality via Newcastle-Ottawa scales. RESULTS: A total of 11,892 records were identified via primary search, 3,223 via citation chasing. Thirty-three studies were identified of 3rd generation vaccines, 32 of which were MVA-BN. Two additional studies were re-analysis of existing data. Most of these studies were focused on gay, bisexual, or other men who have sex with men between the ages of 18-49 in May to October of 2022. VE of 1 dose of MVA-BN was 76% (95%CI 64-88%) from twelve studies. VE of 2 doses was 82% (95%CI 72-92%) from six studies. VE of MVA-BN PEP against mpox was 20% (95%CI -24-65%) from seven studies. All VE are calculated from random effects estimates. 18/33(55%) studies were rated as poor, 3/33(9%) as fair and 12/33(36%) as good. Studies included in the meta-analysis had higher quality: 11/16 (69%) were rated as good quality. CONCLUSION: Both 1 and 2 doses of MVA-BN are highly effective at preventing mpox. Effectiveness estimates, specifically of PEP are limited by immortal time bias, predominant mode of mpox transmission, and real-world vaccine timing of administration.
Cited by
- Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes
- Mpox vaccination coverage among Australian gay and bisexual men and non-binary people: Results of behavioural surveillance in early 2024
- Rapid spread of MPXV clade Ib with high genetic relatedness among men who have sex with men, Berlin, Germany, week 50 2025 up to week 10 2026
- Monkeypox Virus: <scp>WHO</scp> 's Second Public Health Emergency of International Concern Within 2 Years
- Beyond counting the numbers – focused outbreaks response strategies are needed to control the mpox outbreak in Africa
- Monkeypox Virus: Epidemiology, Virology, Diagnosis, Vaccine, and Therapeutics
- Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023. [europepmc]
- Challenges and opportunities in the face of Mpox in Latin America. [europepmc]
- Mpox: Global epidemic situation and countermeasures. [europepmc]
- Monkeypox Virus: WHO's Second Public Health Emergency of International Concern Within 2 Years. [europepmc]
- Epidemiology and Clinical Features of Mpox in Jakarta, Indonesia, August 2022-December 2023. [europepmc]
- Vaccines and Antiviral Therapies for Mpox Virus in Pregnant and Breastfeeding Women: Efficacy and Maternal-Child Outcomes. [europepmc]
- An Mpox Multi-Antigen-Tandem Bivalent mRNA Candidate Vaccine Effectively Protects Mice Against the Vaccinia Virus. [europepmc]
- Current status of next-generation vaccines against mpox virus: a scoping review. [europepmc]
- Recent Advances in Mpox Epidemic: Global Features and Vaccine Prevention Research. [europepmc]
- Ocular Manifestations of Mpox and Other Poxvirus Infections: Clinical Insights and Emerging Therapeutic and Preventive Strategies. [europepmc]
- Mpox 2022 to 2025 Update: A Comprehensive Review on Its Complications, Transmission, Diagnosis, and Treatment. [europepmc]
- Mpox unveiled: Global epidemiology, treatment advances, and prevention strategies. [europepmc]
- Harnessing Artificial Intelligence and Innovative Vaccines for Mpox Diagnosis and Control: A Comprehensive Narrative Review. [europepmc]
- Multivalent mpox protein nanoparticle vaccines confer cross-protection against orthopoxvirus infection. [europepmc]
- Vaccination strategies to achieve outbreak control for MPXV Clade I with a one-time mass campaign in sub-Saharan Africa: A scenario-based modelling study. [europepmc]
- Mpox-Related Stigma Among Gay, Bisexual, and Other Men Who Have Sex with Men: A Narrative Review. [europepmc]
- Characteristics of individuals who received a complete, 2-dose mpox vaccine regimen as part of the public health response to the mpox epidemic in Ontario, Canada. [europepmc]
- Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination. [europepmc]
- Potent neutralization by antibodies targeting the MPXV A28 protein. [europepmc]
- Monkeypox Virus: Epidemiology, Virology, Diagnosis, Vaccine, and Therapeutics. [europepmc]
- Beyond counting the numbers - focused outbreaks response strategies are needed to control the mpox outbreak in Africa. [europepmc]
- Leveraging Google search data for predictive surveillance of Mpox: Toward active outbreak prevention. [europepmc]
- Extensive cryptic circulation sustains mpox among men who have sex with men. [europepmc]
- Rapid spread of MPXV clade Ib with high genetic relatedness among men who have sex with men, Berlin, Germany, week 50 2025 up to week 10 2026. [europepmc]
- Summary of the National Advisory Committee on Immunization (NACI) rapid response: Updated guidance on the use of Imvamune® for the prevention of mpox. [europepmc]
Related